Kilitch Drugs Standalone September 2023 Net Sales at Rs 31.57 crore, up 40.77 percent Y-o-Y - Moneycontrol
| KILITCH Stock | 307.55 0.10 0.03% |
Under 61% of Kilitch Drugs' investor base is looking to short. The analysis of overall sentiment of trading Kilitch Drugs Limited stock suggests that many investors are alarmed at this time. Kilitch Drugs' investing sentiment shows overall attitude of investors towards Kilitch Drugs Limited.
Kilitch |
Kilitch Drugs Standalone September 2023 Net Sales at Rs 31.57 crore, up 40.77 percent Y-o-Y Moneycontrol
Read at news.google.com
 |
Kilitch Drugs Fundamental Analysis
We analyze Kilitch Drugs' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kilitch Drugs using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kilitch Drugs based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
Kilitch Drugs is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Kilitch Drugs Limited Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kilitch Drugs stock to make a market-neutral strategy. Peer analysis of Kilitch Drugs could also be used in its relative valuation, which is a method of valuing Kilitch Drugs by comparing valuation metrics with similar companies.
Peers
Kilitch Drugs Related Equities
| NEOGEN | Neogen Chemicals | 8.01 | ||||
| TIRUMALCHM | Thirumalai Chemicals | 6.88 | ||||
| DMCC | DMCC SPECIALITY | 1.46 | ||||
| TATACHEM | Tata Chemicals | 1.23 | ||||
| EMBASSY | EMBASSY OFFICE | 0.39 | ||||
| POCL | Pondy Oxides | 1.22 | ||||
| SUMICHEM | Sumitomo Chemical | 2.45 |
Complementary Tools for Kilitch Stock analysis
When running Kilitch Drugs' price analysis, check to measure Kilitch Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kilitch Drugs is operating at the current time. Most of Kilitch Drugs' value examination focuses on studying past and present price action to predict the probability of Kilitch Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kilitch Drugs' price. Additionally, you may evaluate how the addition of Kilitch Drugs to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |